Advanced Biomed Executes Reverse Split to Maintain Nasdaq Listing

An update from Advanced Biomed Inc. ( (ADVB) ) is now available.

Advanced Biomed Inc. implemented a 1-for-20 reverse stock split of its common shares, approved by majority written consent on January 12, 2026 and set by the board on January 30, 2026, with the amendment filed in Nevada on February 3, 2026. The split took effect at the open of trading on Nasdaq on February 20, 2026, converting every 20 issued and outstanding shares into one while keeping the $0.001 par value unchanged.

As part of the consolidation, the company’s issued and outstanding common shares fell from 27,290,710 to roughly 1,364,536, while the authorized share count remained the same. Fractional shares were not issued, with positions rounded up to whole shares, and the stock continues to trade under the ADVB ticker with a new CUSIP, a move aimed at regaining compliance with Nasdaq’s $1.00 minimum bid price requirement and stabilizing its market listing.

More about Advanced Biomed Inc.

Advanced Biomed Inc., a Nevada-based biotechnology company, specializes in innovative biomedical technologies for cancer detection and precision medicine. Operating through a subsidiary in Taiwan, it has developed a proprietary microfluidic platform that combines semiconductor and biotech to enable advanced circulating tumor cell detection, enrichment and analysis for oncology applications.

Its portfolio includes devices and biochips designed for cancer screening, diagnosis, treatment selection and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for future global expansion. The company’s shares trade on the Nasdaq Capital Market under the symbol ADVB, targeting international growth in precision oncology diagnostics.

Average Trading Volume: 52,961

Technical Sentiment Signal: Strong Sell

Current Market Cap: $5.08M

See more data about ADVB stock on TipRanks’ Stock Analysis page.